Entera Bio (NASDAQ:ENTX) Posts Earnings Results, Beats Estimates By $0.02 EPS

Entera Bio (NASDAQ:ENTX) posted its quarterly earnings results on Friday. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.02, Zacks reports.

Entera Bio Stock Performance

Shares of NASDAQ ENTX opened at $1.13 on Friday. The business has a 50 day simple moving average of $1.37 and a 200 day simple moving average of $1.89. Entera Bio has a 52 week low of $0.98 and a 52 week high of $3.22. The stock has a market cap of $51.82 million, a price-to-earnings ratio of -4.35 and a beta of 1.83.

Analysts Set New Price Targets

ENTX has been the topic of a number of research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Entera Bio in a research report on Thursday, January 22nd. HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of Entera Bio in a research note on Monday, February 9th. Finally, Wall Street Zen upgraded shares of Entera Bio to a “sell” rating in a report on Saturday, December 27th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $10.00.

Insiders Place Their Bets

In other Entera Bio news, Director Geno J. Germano acquired 20,000 shares of the business’s stock in a transaction that occurred on Monday, March 9th. The shares were purchased at an average price of $1.30 per share, with a total value of $26,000.00. Following the completion of the transaction, the director owned 40,000 shares in the company, valued at $52,000. The trade was a 100.00% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders have purchased a total of 69,000 shares of company stock worth $92,530 over the last 90 days. 10.38% of the stock is currently owned by company insiders.

Institutional Trading of Entera Bio

Large investors have recently added to or reduced their stakes in the business. Superstring Capital Management LP bought a new position in shares of Entera Bio during the 4th quarter valued at $33,000. Schonfeld Strategic Advisors LLC boosted its holdings in Entera Bio by 5.2% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 596,585 shares of the company’s stock worth $1,157,000 after purchasing an additional 29,629 shares in the last quarter. Jane Street Group LLC boosted its holdings in Entera Bio by 142.6% in the fourth quarter. Jane Street Group LLC now owns 74,064 shares of the company’s stock worth $144,000 after purchasing an additional 43,536 shares in the last quarter. Renaissance Technologies LLC increased its position in Entera Bio by 22.2% during the fourth quarter. Renaissance Technologies LLC now owns 108,001 shares of the company’s stock worth $210,000 after buying an additional 19,601 shares during the last quarter. Finally, HighTower Advisors LLC increased its position in Entera Bio by 137.8% during the fourth quarter. HighTower Advisors LLC now owns 43,140 shares of the company’s stock worth $84,000 after buying an additional 25,000 shares during the last quarter. 14.11% of the stock is owned by institutional investors.

Entera Bio Company Profile

Entera Bio, Inc is a clinical‐stage biopharmaceutical company pioneering the development of orally delivered peptide therapeutics. Utilizing its proprietary oral delivery platform, Entera Bio seeks to overcome the challenges of gastrointestinal absorption for large peptide molecules. The technology is designed to facilitate transit across the intestinal epithelium while preserving peptide structure and bioactivity, offering the potential for daily oral dosing in lieu of injectable formulations.

The company’s lead candidate, EB613, is an oral parathyroid hormone (PTH) analog under investigation for the treatment of osteoporosis.